Skip to main content
Clinical Trials/EUCTR2020-000819-67-GB
EUCTR2020-000819-67-GB
Active, not recruiting
Phase 1

SENTINUS: Technical feasibility and diagnostic accuracy of intradermal microbubbles and contrast enhanced ultrasound to identify sentinel lymph node metastases in breast cancer patients following training and mentorship of imaging specialists - SENTINUS

Maidstone and Tunbridge Wells NHS Trust0 sites250 target enrollmentStarted: June 10, 2020Last updated:

Overview

Phase
Phase 1
Status
Active, not recruiting
Enrollment
250

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
Female

Inclusion Criteria

  • Histologically confirmed invasive carcinoma of the breast without palpable axillary lymph nodes with planned
  • primary surgical treatment.
  • Normal B\-mode axillary ultrasound or benign biopsy of morphologically abnormal lymph nodes.
  • Participant is willing and able to give informed consent for participation in the trial.
  • Aged 18 years or above.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 175
  • F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • Previous ipsilateral breast cancer treated with radiotherapy or chemotherapy or recurrent breast cancer.
  • Female participant who is pregnant, lactating or planning fertility preservation during the course of the
  • Allergy to contrast.
  • Inflammatory or locally advanced breast cancer.
  • Metastatic breast cancer.
  • Inability to raise ipsilateral arm above head.
  • Multiple medical co\-morbidities (ASA 4 or above).
  • Previous ipsilateral axillary surgery.

Investigators

Similar Trials